AIP
IONS icon

Almanack Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Almanack Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$44K – 661
2022
Q3 		$44K Buy
+1,000
New +$42.1K 0.01% 281

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Almanack Investment Partners's IONS Position: Q4 2022 in Review

Almanack Investment Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 1,000 shares — an estimated $44K sold.

Almanack Investment Partners first reported a position in IONS in Q3 2022 and held it in 1 quarter. The position peaked at $44K in Q3 2022. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • Almanack Investment Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 1,000 Ionis Pharmaceuticals shares in Q4 2022, an estimated $44K.
  • Almanack Investment Partners first reported a position in Ionis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Ionis Pharmaceuticals position peaked at $44K in Q3 2022.
  • 338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.